Eculizumab in refractory myasthenic crisis
2018; Wiley; Volume: 58; Issue: 2 Linguagem: Inglês
10.1002/mus.26124
ISSN1097-4598
AutoresCrystal Jing Jing Yeo, Milvia Pleitez,
Tópico(s)Antifungal resistance and susceptibility
ResumoMuscle & NerveVolume 58, Issue 2 p. E13-E15 Noteworthy Cases Eculizumab in refractory myasthenic crisis Crystal Jing Jing Yeo MD, PhD, Crystal Jing Jing Yeo MD, PhD Houston Methodist Neurological Institute, Houston Methodist Hospital, Texas Medical Center, Houston, TexasSearch for more papers by this authorMilvia Y. Pleitez MD, Milvia Y. Pleitez MD Houston Methodist Neurological Institute, Houston Methodist Hospital, Texas Medical Center, Houston, TexasSearch for more papers by this author Crystal Jing Jing Yeo MD, PhD, Crystal Jing Jing Yeo MD, PhD Houston Methodist Neurological Institute, Houston Methodist Hospital, Texas Medical Center, Houston, TexasSearch for more papers by this authorMilvia Y. Pleitez MD, Milvia Y. Pleitez MD Houston Methodist Neurological Institute, Houston Methodist Hospital, Texas Medical Center, Houston, TexasSearch for more papers by this author First published: 10 March 2018 https://doi.org/10.1002/mus.26124Citations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume58, Issue2August 2018Pages E13-E15 RelatedInformation
Referência(s)